Claudia Sommerer

List of Publications by Year
in descending order

102	3,357	159585 30	161849 54
papers	citations	h-index	g-index

104	104	104	3247
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV. International Journal of Molecular Sciences, 2022, 23, 1029.	4.1	1
2	Educational Attainment Is Associated With Kidney and Cardiovascular Outcomes in the German CKD (GCKD) Cohort. Kidney International Reports, 2022, 7, 1004-1015.	0.8	8
3	Incidences of Infectious Events in a Renal Transplant Cohort of the German Center of Infectious Diseases (DZIF). Open Forum Infectious Diseases, 2022, 9, .	0.9	7
4	Effect of everolimusâ€based drug regimens on CMVâ€specific Tâ€cell functionality after renal transplantation: 12â€month ATHENA subcohortâ€study results. European Journal of Immunology, 2021, 51, 943-955.	2.9	9
5	Spectrum and dosing of urate-lowering drugs in a large cohort of chronic kidney disease patients and their effect on serum urate levels: a cross-sectional analysis from the German Chronic Kidney Disease study. CKJ: Clinical Kidney Journal, 2021, 14, 277-283.	2.9	1
6	Early prognostic performance of miR155-5p monitoring for the risk of rejection: Logistic regression with a population pharmacokinetic approach in adult kidney transplant patients. PLoS ONE, 2021, 16, e0245880.	2.5	9
7	Peptide Vaccination against Cytomegalovirus Induces Specific T Cell Response in Responses in CMV Seronegative End-Stage Renal Disease Patients. Vaccines, 2021, 9, 133.	4.4	8
8	Monitoring of gene expression in tacrolimusâ€treated de novo renal allograft recipients facilitates individualized immunosuppression: Results of the IMAGEN study. British Journal of Clinical Pharmacology, 2021, 87, 3851-3862.	2.4	6
9	Bioimpedance analysis is not superior to clinical assessment in determining hydration status: A prospective randomizedâ€controlled trial in a Western dialysis population. Hemodialysis International, 2021, 25, 380-390.	0.9	4
10	Advantages of plasmatic CXCL-10 as a prognostic and diagnostic biomarker for the risk of rejection and subclinical rejection in kidney transplantation. Clinical Immunology, 2021, 229, 108792.	3.2	6
11	Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: proof-of-concept study. BMJ Open, 2021, 11, e052138.	1.9	24
12	Soluble Urokinase Receptor and Mortality in Kidney Transplant Recipients. Transplant International, 2021, 35, 10071.	1.6	2
13	Living Donor Kidney Transplantation in Patients With Donor-Specific HLA Antibodies After Desensitization With Immunoadsorption. Frontiers in Medicine, 2021, 8, 781491.	2.6	3
14	Status of periodontal health in German patients suffering from chronic kidney diseaseâ€"Data from the GCKD study. Journal of Clinical Periodontology, 2020, 47, 19-29.	4.9	15
15	P0782PROGNOSTIC IMPACT OF NECK CIRCUMFERENCE ON CARDIVASCULAR OUTCOMES AND MORTALITY IN PATIENTS WITH MODERATE CHRONIC KIDNEY DISEASE: AN ANALYSIS FROM THE GERMAN CHRONIC KIDNEY DISEASE (GCKD) STUDY. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
16	Association of Serum Uromodulin with Death, Cardiovascular Events, and Kidney Failure in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 616-624.	4.5	25
17	Should kidney allografts from old donors be allocated only to old recipients?. Transplant International, 2020, 33, 849-857.	1.6	12
18	Novel Biomarkers in Patients with Chronic Kidney Disease: An Analysis of Patients Enrolled in the GCKD-Study. Journal of Clinical Medicine, 2020, 9, 886.	2.4	15

#	Article	IF	Citations
19	After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney International, 2020, 98, 1044-1052.	5.2	103
20	Phase I trial of donor-derived modified immune cell infusion in kidney transplantation. Journal of Clinical Investigation, 2020, 130, 2364-2376.	8.2	29
21	Outcomes and complications following ABOâ€incompatible kidney transplantation performed after desensitization by semiâ€selective immunoadsorption â€•a retrospective study. Transplant International, 2019, 32, 1286-1296.	1.6	18
22	Evidence-based practice: Guidance for using everolimus in combination with low-exposure calcineurin inhibitors as initial immunosuppression in kidney transplant patients. Transplantation Reviews, 2019, 33, 191-199.	2.9	12
23	Everolimus in de novo kidney transplant recipients participating in the Eurotransplant senior program: Results of a prospective randomized multicenter study (SENATOR). PLoS ONE, 2019, 14, e0222730.	2.5	7
24	Effectiveness of different immunoadsorption columns for anti-A/B antibody depletion. Atherosclerosis Supplements, 2019, 40, 68-72.	1.2	3
25	Soluble urokinase plasminogen activation receptor and long-term outcomes in persons undergoing coronary angiography. Scientific Reports, 2019, 9, 475.	3.3	8
26	Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study. American Journal of Transplantation, 2019, 19, 3018-3034.	4.7	97
27	An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in deÂnovo kidney transplant patients. Kidney International, 2019, 96, 231-244.	5.2	69
28	7â€…Modified immune cell therapy ameliorates murine lupus nephritis and induces regulatory cell subsets. , 2019, , .		0
29	OP0040â€…MODIFIED IMMUNE CELL THERAPY AMELIORATES MURINE LUPUS NEPHRITIS AND INDUCES REGULATORY CELL SUBSETS. , 2019, , .		0
30	A need-adapted transition program after pediatric kidney transplantation. Journal of Transition Medicine, 2019, 1, .	0.5	7
31	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Therapeutic Drug Monitoring, 2019, 41, 261-307.	2.0	374
32	Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study. Transplantation, 2019, 103, 1953-1963.	1.0	69
33	Clinical validation of a novel enzyme-linked immunosorbent spot assay-basedinÂvitrodiagnostic assay to monitor cytomegalovirus-specific cell-mediated immunity in kidney transplant recipients: a multicenter, longitudinal, prospective, observational study. Transplant International, 2018, 31, 436-450.	1.6	30
34	Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy. American Journal of Transplantation, 2018, 18, 2965-2976.	4.7	11
35	Endâ€stage renal disease, dialysis, kidney transplantation and their impact on <scp>CD</scp>4⁺ Tâ€cell differentiation. Immunology, 2018, 155, 211-224.	4.4	34
36	Improved Pulse Wave Velocity and Renal Function in Individualized Calcineurin Inhibitor Treatment by Immunomonitoring. Transplantation, 2018, 102, 510-520.	1.0	7

#	Article	IF	Citations
37	Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2018, 29, 317-325.	6.1	64
38	Gender disparity in health-related quality of life and fatigue after living renal donation. BMC Nephrology, 2018, 19, 377.	1.8	10
39	1575. Clinical Validation of a Novel ELISpot-based in vitro Diagnostic Assay to Monitor CMV-Specific Cell-Mediated Immunity in SOT and HSCT Immunocompromised Patients. Open Forum Infectious Diseases, 2018, 5, S491-S492.	0.9	0
40	Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials. BMC Nephrology, 2018, 19, 237.	1.8	14
41	Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2018, 29, 1979-1991.	6.1	193
42	Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS study. BMC Nephrology, 2018, 19, 154.	1.8	3
43	Blood pressure control in chronic kidney disease: A cross-sectional analysis from the German Chronic Kidney Disease (GCKD) study. PLoS ONE, 2018, 13, e0202604.	2.5	20
44	Induction of Donor-Specific Immune Tolerance with Clinical MIC Cell Infusion â€" a Phase I Study (TOL-1). Blood, 2018, 132, 4539-4539.	1.4	0
45	An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade. Expert Opinion on Pharmacotherapy, 2017, 18, 799-807.	1.8	6
46	Switch to an everolimusâ€facilitated cyclosporine A sparing immunosuppression improves glycemic control in selected kidney transplant recipients. Clinical Transplantation, 2017, 31, e13024.	1.6	11
47	Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial. Nephrology Dialysis Transplantation, 2017, 32, 1060-1070.	0.7	31
48	Urinary miRâ€155â€5p and CXCL10 as prognostic and predictive biomarkers of rejection, graft outcome and treatment response in kidney transplantation. British Journal of Clinical Pharmacology, 2017, 83, 2636-2650.	2.4	49
49	The role of ageâ€related Tâ€cell differentiation in patients with renal replacement therapy. Immunology and Cell Biology, 2017, 95, 895-905.	2.3	6
50	Correlation between pharmacokinetics of tacrolimus and pharmacodynamics on NFAT-regulated gene expression in stable kidney transplant recipients. Clinical Nephrology, 2017, 87, 93-99.	0.7	12
51	Glycaemic control and antidiabetic therapy in patients with diabetes mellitus and chronic kidney disease â€" cross-sectional data from the German Chronic Kidney Disease (GCKD) cohort. BMC Nephrology, 2016, 17, 59.	1.8	18
52	Overhydration Is a Strong Predictor of Mortality in Peritoneal Dialysis Patients â€" Independently of Cardiac Failure. PLoS ONE, 2016, 11, e0158741.	2.5	34
53	Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation. Therapeutic Drug Monitoring, 2016, 38, S1-S20.	2.0	78
54	Analytical Aspects of the Implementation of Biomarkers in Clinical Transplantation. Therapeutic Drug Monitoring, 2016, 38, S80-S92.	2.0	6

#	Article	IF	Citations
55	Target Enzyme Activity and Phosphorylation of Pathway Molecules As Specific Biomarkers in Transplantation. Therapeutic Drug Monitoring, 2016, 38, S43-S49.	2.0	6
56	Reporting Quality-of-Life Outcomes in Clinical Trials of Immunosuppressive Therapy in Kidney Transplantation. American Journal of Kidney Diseases, 2016, 67, 722-723.	1.9	3
57	Analytical Validation and Cross-Validation of an NFAT-Regulated Gene Expression Assay for Pharmacodynamic Monitoring of Therapy With Calcineurin Inhibitors. Therapeutic Drug Monitoring, 2016, 38, 711-716.	2.0	8
58	Design and rationale of the ATHENA study â€“ A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial. Trials, 2016, 17, 92.	1.6	11
59	Nuclear Factor of Activated T Cellsâ€“Regulated Gene Expression as Predictive Biomarker of Personal Response to Calcineurin Inhibitors. Therapeutic Drug Monitoring, 2016, 38, S50-S56.	2.0	21
60	Everolimus immunosuppression in kidney transplantation: What is the optimal strategy?. Transplantation Reviews, 2016, 30, 3-12.	2.9	21
61	Early conversion from cyclosporine to everolimus following living-donor kidney transplantation: outcomes at 5 years posttransplant in the randomized ZEUS trial. Clinical Nephrology, 2016, 85 (2016), 215-225.	0.7	9
62	Evolution of allograft fibrosis and function in kidney transplant recipients: a retrospective analysis of stable patients under CNI and mTORi. Transplant International, 2015, 28, 553-564.	1.6	12
63	Psychosocial and physical outcome following kidney donation-a retrospective analysis. Transplant International, 2015, 28, 416-428.	1.6	26
64	Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study. Clinical Nephrology, 2015, 83 (2015), 11-21.	0.7	33
65	Secreted frizzled-related protein 4 predicts progression of autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2015, 31, gfv077.	0.7	9
66	High interpatient variability in response to mycophenolic acid maintenance therapy in patients with ANCA-associated vasculitis. Nephrology Dialysis Transplantation, 2015, 30, i138-i145.	0.7	10
67	Renal function to 5Âyears after late conversion of kidney transplant patients to everolimus: a randomized trial. Journal of Nephrology, 2015, 28, 115-123.	2.0	16
68	Monitoring of calcineurin inhibitors by NFATregulated gene expression in de novo renal allograft recipients on cyclosporine A. Clinical Nephrology, 2015, 84 (2015), 165-172.	0.7	9
69	The Calcineurin Inhibitor-Sparing (CIS) Trial - individualised calcineurin-inhibitor treatment by immunomonitoring in renal allograft recipients: protocol for a randomised controlled trial. Trials, 2014, 15, 489.	1.6	13
70	Pharmacodynamic monitoring of nuclear factor of activated T cell-regulated gene expression in liver allograft recipients on immunosuppressive therapy with calcineurin inhibitors in the course of time and correlation with acute rejection episodes â€“ a prospective study. Annals of Transplantation, 2014, 19, 32-40.	0.9	25
71	Current pharmacotherapeutical options for the prevention of kidney transplant rejection. Expert Opinion on Pharmacotherapy, 2013, 14, 1029-1041.	1.8	2
72	Assessment of renal allograft fibrosis by transient elastography. Transplant International, 2013, 26, 545-551.	1.6	58

#	Article	IF	Citations
73	Calcineurin inhibitors and NFAT-regulated gene expression. Clinica Chimica Acta, 2012, 413, 1379-1386.	1.1	41
74	Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy. Transplant International, 2012, 25, 506-517.	1.6	59
75	Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet, The, 2011, 377, 837-847.	13.7	326
76	Safety and Efficacy of Intensified Versus Standard Dosing Regimens of Enteric-Coated Mycophenolate Sodium in De Novo Renal Transplant Patients. Transplantation, 2011, 91, 779-785.	1.0	26
77	Pharmacodynamic Disparities in Tacrolimus-Treated Patients Developing Cytomegalus Virus Viremia. Therapeutic Drug Monitoring, 2011, 33, 373-379.	2.0	25
78	Cyclosporineâ€induced gingival overgrowth correlates with NFATâ€regulated gene expression: a pilot study. Journal of Clinical Periodontology, 2011, 38, 984-991.	4.9	9
79	Immunomonitoring of nuclear factor of activated T cells-regulated gene expression: The first clinical trial in liver allograft recipients. Liver Transplantation, 2011, 17, 466-473.	2.4	26
80	Pharmacodynamic Monitoring of Cyclosporin A Reveals Risk of Opportunistic Infections and Malignancies in Renal Transplant Recipients 65 Years and Older. Therapeutic Drug Monitoring, 2011, 33, 694-698.	2.0	32
81	Biomarkers as a Tool for Management of Immunosuppression in Transplant Patients. Therapeutic Drug Monitoring, 2010, 32, 560-572.	2.0	54
82	Individualized Monitoring of Nuclear Factor of Activated T Cells-Regulated Gene Expression in FK506-Treated Kidney Transplant Recipients. Transplantation, 2010, 89, 1417-1423.	1.0	43
83	Pharmacokinetic and pharmacodynamic analysis of entericâ€coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. British Journal of Clinical Pharmacology, 2010, 69, 346-357.	2.4	57
84	Pharmacodynamic monitoring of cyclosporine A by NFATâ€regulated gene expression and the relationship with infectious complications in pediatric renal transplant recipients. Pediatric Transplantation, 2010, 14, 844-851.	1.0	20
85	Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil. Rheumatology, 2010, 49, 2061-2067.	1.9	41
86	Pharmacokinetics and Pharmacodynamics of Intensified versus Standard Dosing of Mycophenolate Sodium in Renal Transplant Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 503-511.	4.5	40
87	Approaches towards Individualized Immune Intervention. Digestive Diseases, 2010, 28, 45-50.	1.9	10
88	New concepts to individualize calcineurin inhibitor therapy in renal allograft recipients. Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2010, 21, 1030-7.	0.3	4
89	Role of FTY720 on M1 and M2 macrophages, lymphocytes, and chemokines in atchmode documentclass[fleqn,10pt,legalpaper]{article} usepackage{amssymb} usepackage{amsfonts} usepackage{amsmath} pagestyle{empty} egin{document} ({5}/{6}) end{document} nephrectomized rats. American Journal of Physiology - Renal Physiology, 2009, 297, F769-F780.	2.7	26
90	AEB071 â€“ a promising immunosuppressive agent. Clinical Transplantation, 2009, 23, 15-18.	1.6	10

#	Article	IF	Citations
91	Monitoring immunosuppression with measures of NFAT decreases cancer incidence. Clinical Immunology, 2009, 132, 305-311.	3.2	18
92	Pharmacodynamic immune monitoring of NFATâ€regulated genes predicts skin cancer in elderly longâ€term renal transplant recipients. Clinical Transplantation, 2008, 22, 549-554.	1.6	39
93	Pharmacodynamic monitoring of calcineurin inhibitor therapy: Is there a clinical benefit?. Nephrology Dialysis Transplantation, 2008, 24, 21-27.	0.7	39
94	Ciclosporin A Tapering Monitored by NFAT-Regulated Gene Expression: A New Concept of Individual Immunosuppression. Transplantation, 2008, 85, 15-21.	1.0	60
95	Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients. Journal of Hypertension, 2008, 26, 2213-2219.	0.5	50
96	Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial. Transplantation, 2008, 86, 1043-1051.	1.0	238
97	Cardiac Biomarkers in Haemodialysis Patients: The Prognostic Value of Amino-Terminal Pro-B-Type Natriuretic Peptide and Cardiac Troponin T. Nephron Clinical Practice, 2007, 107, c77-c81.	2.3	18
98	Rapid deterioration of renal function in a long-term allograft recipient with recurrent IgA nephritis is it the only cause?. Nephrology Dialysis Transplantation, 2007, 22, 3079-3081.	0.7	0
99	Pharmacodynamic cyclosporine A-monitoring: relation of gene expression in lymphocytes to cyclosporine blood levels in cardiac allograft recipients. Transplant International, 2007, 20, 1036-1043.	1.6	35
100	Pharmacodynamic Monitoring of Cyclosporine A in Renal Allograft Recipients Shows a Quantitative Relationship Between Immunosuppression and the Occurrence of Recurrent Infections and Malignancies. Transplantation, 2006, 82, 1280-1285.	1.0	75
101	The long-term consequences of living-related or unrelated kidney donation. Nephrology Dialysis Transplantation, 2004, 19, iv45-iv47.	0.7	28
102	Cyclosporin A Toxicity of the Renal Allograft â€“ a Late Complication and Potentially Reversible. Nephron, 2002, 92, 339-345.	1.8	27